Microplastics and Misinformation: What Science Really Says
November 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Aristada
Synonyms :
aripiprazole lauroxil
Class :
Antipsychotic
Brand Name :
Aristada
Synonyms :
aripiprazole lauroxil
Class :
Antipsychotic
Dosage Forms & StrengthsÂ
Injectable SuspensionÂ
675 mg (Aristada Initio)Â
441 mg (Aristada)Â
662 mg (Aristada)Â
882 mg (Aristada)Â
1064 mg (Aristada)Â
Indicated for Schizophrenia
Initial dose: 30 mg orally for one day, one dose of 675 mg of nanocrystal dispersion with the 1st dose of the aripiprazole lauroxil depending on ongoing aripiprazole dose with/within ten days following administering 675 mg dose
Or
21-day orally overlap: Administer aripiprazole orally for 21 days combined with 1st dose of the aripiprazole lauroxil depending on the ongoing aripiprazole dose
Turning of aripiprazole oral form to intramuscular aripiprazole lauroxil (i.e.,Aristada)
aripiprazole orally 10 mg in a day: Initial intramuscular aripiprazole lauroxil (i.e.,Aristada) dose: 441 mg for a month
aripiprazole orally 15 mg in a day: Initial intramuscular aripiprazole lauroxil (i.e., Aristada) dose: 662 mg for a month or 882 mg every six weeks or 1064 mg every two months
aripiprazole orally >20 mg in a day: Initial intramuscular aripiprazole lauroxil (i.e.,Aristada) dose: 882 mg for a month
Note:
Dose adjustment: Modify aripiprazole lauroxil dose as per requirement; if the dose is needed before then, the recommended interval, Should not administer <14 days following the earlier injection
Safety and efficacy not establishedÂ
Refer to adult dosingÂ
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish serum concentrations when combined with aripiprazole lauroxil
may diminish serum concentrations when combined with aripiprazole lauroxil
may diminish serum concentrations when combined with aripiprazole lauroxil
may diminish serum concentrations when combined with aripiprazole lauroxil
may diminish serum concentrations when combined with aripiprazole lauroxil
aripiprazole lauroxil: they may enhance the serum concentration of CYP2D6 Inhibitors
aripiprazole lauroxil: they may enhance the serum concentration of CYP2D6 Inhibitors
aripiprazole lauroxil: they may enhance the serum concentration of CYP2D6 Inhibitors
aripiprazole lauroxil: they may enhance the serum concentration of CYP2D6 Inhibitors
aripiprazole lauroxil: they may enhance the serum concentration of CYP2D6 Inhibitors
CYP3A enhancers may decrease plasma concentrations of the active metabolite(s) of aripiprazole lauroxil
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
It may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
may enhance the concentration of serum when combined with aripiprazole lauroxil
may enhance the concentration of serum when combined with aripiprazole lauroxil
may enhance the concentration of serum when combined with aripiprazole lauroxil
may enhance the concentration of serum when combined with aripiprazole lauroxil
may enhance the concentration of serum when combined with aripiprazole lauroxil
may diminish the concentration of serum when combined with aripiprazole lauroxil
may diminish the concentration of serum when combined with aripiprazole lauroxil
The orthostatic hypotensive effects of aripiprazole lauroxil may be enhanced by levobetaxolol
aripiprazole lauroxil: they may increase the hypotensive effect of blood viscosity reducing agents
aripiprazole lauroxil: they may increase the hypotensive effect of blood viscosity reducing agents
may diminish the therapeutic effect of the drug
combining indalpine with aripiprazole lauroxil may result in a decreased metabolism of aripiprazole lauroxil
the therapeutic effectiveness of insulin aspart can be decreased when used in conjunction with aripiprazole lauroxil
the hazard or seriousness of QTc prolongation can be heightened when digitoxin is combined with aripiprazole lauroxil
serotonergic Agents may enhance the adverse/toxic effect of antipsychotic Agents
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the risk of adverse effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
it may enhance the metabolism when combined with aripiprazole lauroxil
it may diminish the metabolism when combined with aripiprazole lauroxil
it may enhance the risk of CNS depression when combined with aripiprazole lauroxil
it may enhance the risk of cns depression when combined with aripiprazole lauroxil
it may diminish the metabolism when combined with aripiprazole lauroxil
it may diminish the metabolism when combined with aripiprazole lauroxil
it may diminish the metabolism when combined with aripiprazole lauroxil
it may diminish the metabolism when combined with aripiprazole lauroxil
it may enhance the metabolism when combined with aripiprazole lauroxil
it may enhance the metabolism when combined with aripiprazole lauroxil
it may enhance the metabolism when combined with aripiprazole lauroxil
it may enhance the metabolism when combined with aripiprazole lauroxil
it may enhance the metabolism when combined with aripiprazole lauroxil
it may diminish the metabolism when combined with aripiprazole lauroxil
it may enhance the metabolism when combined with aripiprazole lauroxil
it may diminish the metabolism when combined with aripiprazole lauroxil
it may diminish the metabolism when combined with aripiprazole lauroxil
it may diminish the metabolism when combined with aripiprazole lauroxil
it may enhance the metabolism when combined with aripiprazole lauroxil
it may enhance the metabolism when combined with aripiprazole lauroxil
it may enhance the metabolism when combined with aripiprazole lauroxil
it may enhance the metabolism when combined with aripiprazole lauroxil
it may diminish the metabolism when combined with aripiprazole lauroxil
it may diminish the metabolism when combined with aripiprazole lauroxil
it may diminish the metabolism when combined with aripiprazole lauroxil
It may enhance the toxicity when combined with mipomersen
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may have an increased effect of CNS depression when combined with Aripiprazole lauroxil
the rate of metabolism of aripiprazole lauroxil may be reduced
When aripiprazole lauroxil is used together in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
Actions and Spectrum:Â
aripiprazole lauroxil is an antipsychotic medication used to treat schizophrenia and bipolar disorder. It is a long-acting injectable form of aripiprazole, a partial agonists of the dopamine D2 receptors and the serotonin 5-HT1A receptor, and an antagonist of the serotonin 5-HT2A receptor.Â
The action of aripiprazole lauroxil is believed to be linked to its ability to modify the activity of dopamine, serotonin in the brain. By working as partial agonist at the D2 receptor, it can help regulate the levels of dopamine, which is a neurotransmitter that is generally associated with the symptoms of schizophrenia and bipolar disorder. By working as an antagonist at the 5-HT2A receptor, it can help reduce the activity of serotonin, which is also implicated in the development of these disorders.Â
The spectrum of aripiprazole lauroxil refers to the range of symptoms and conditions that it is effective in treating. aripiprazole lauroxil is primarily used to treat the positive symptoms of schizophrenia, like delusions and also hallucinations, as well as the manic and mixed episodes of bipolar disorder. It may also be generally used to treat the negative symptoms of schizophrenia, like social withdrawal and apathy, although its effectiveness is less well-established.Â
Frequency definedÂ
>10%Â
Akathisia (11%)Â
1-10%Â
Weight gainÂ
headache Â
DystoniaÂ
Injection site reactionÂ
insomnia Â
extrapyramidal reactionÂ
parkinsonism Â
Enhanced creatine phosphokinaseÂ
Orthostatic hypotensionÂ
ErythemaÂ
Frequency not definedÂ
Angina pectorisÂ
TachycardiaÂ
PalpitationsÂ
XerostomiaÂ
Black Box Warning:Â
The black box warning for aripiprazole lauroxil is related to an enhanced risk of death in elderly patients with dementia-related psychosis. aripiprazole lauroxil is not approved for treatment of patients with dementia-related psychosis. Still, older patients with dementia-related psychosis treated with antipsychotic drugs are at an enhanced risk of death compared to placebo.Â
The warning states that aripiprazole lauroxil is not approved for treating patients with dementia-related psychosis and that older patients with dementia-related psychosis generally treated with antipsychotic drugs are at an enhanced risk of death. The warning also advises healthcare providers to consider the risks and benefits of aripiprazole lauroxil before prescribing it to elderly patients with other conditions, such as schizophrenia or bipolar disorder.
Healthcare providers are also advised to monitor these patients for symptoms such as fever, muscle stiffness, and changes in mental status, which may indicate the development of a potentially life-threatening condition generally known as neuroleptic malignant syndrome (NMS).Â
Contraindication/Caution:Â
ContraindicationÂ
aripiprazole lauroxil has several contraindications, including conditions or situations where the medication should not be used. These include:Â
CautionÂ
aripiprazole lauroxil has several cautions, which are conditions or situations where the medication should be used with caution and careful monitoring. These include:Â
Pregnancy consideration:Â Â
US FDA pregnancy category: Not assignedÂ
Lactation:  Â
Excreted into human milk is Not known.Â
Pregnancy category:Â
Pharmacology:Â
aripiprazole lauroxil is an atypical antipsychotic medication that is a prodrug of aripiprazole. Once injected, aripiprazole lauroxil is slowly metabolized to aripiprazole, the active ingredient responsible for the medication’s pharmacological effects.Â
aripiprazole works by blocking the activity of certain neurotransmitters in the brain, including dopamine and also serotonin, which are involved in developing schizophrenia and bipolar disorder. Unlike other antipsychotic medications, aripiprazole acts as a partial agonist at dopamine D2, serotonin 5-HT1A receptors, which means both activate and inhibit the activity of these receptors depending on the level of dopamine or serotonin in the brain. This unique mechanism of action is believed to contribute to aripiprazole’s effectiveness in treating both positive and also negative symptoms of schizophrenia and bipolar disorder and reducing the risk of extrapyramidal side effects.Â
Pharmacodynamics:Â
Mechanism of action: The drug, aripiprazole lauroxil is a prodrug of aripiprazole, an atypical antipsychotic medication. The active ingredient, aripiprazole, works by blocking or modulating the activity of several neurotransmitters in the brain, including dopamine and serotonin.Â
Pharmacokinetics:Â
AbsorptionÂ
After intramuscular injection, aripiprazole lauroxil is slowly absorbed into the bloodstream. The absorption of the medication is controlled by the hydrophobicity of the molecule, which results in a slow release of aripiprazole over a period of several weeks.Â
DistributionÂ
Once absorbed into the bloodstream, aripiprazole is distributed to many tissues in the body, like in the brain. The protein binding of aripiprazole is approximately 99%, which means that only a small quantity of the medication is unbound and available for distribution.Â
MetabolismÂ
aripiprazole is primarily metabolized by the liver through the cytochrome P450 system, with the majority of the medication being metabolized into its active metabolite, dehydro-aripiprazole. Dehydro-aripiprazole has similar pharmacological properties to aripiprazole and is also partially responsible for the medication’s therapeutic effects.Â
Elimination and ExcretionÂ
aripiprazole and its metabolites are eliminated primarily in the feces, with a small quantity in the urine. The elimination half-life of aripiprazole is approximately 75 hours, meaning it takes approximately two weeks for the medication to be excreted from the body.Â
Administration:Â
aripiprazole lauroxil is a long-acting injectable medication that a healthcare provider administers. Here are some essential considerations for the administration of aripiprazole lauroxil:Â
Patient information leafletÂ
Generic Name: aripiprazole lauroxilÂ
Why do we use aripiprazole lauroxil?Â
aripiprazole lauroxil is an antipsychotic medication for treating schizophrenia and bipolar I disorder in adults. Here are some details about the uses of aripiprazole lauroxil:Â
aripiprazole lauroxil works by blocking the activity of certain types of the neurotransmitters in the brain, including dopamine, serotonin, which are involved in developing schizophrenia and bipolar disorder.Â
It is important to note that aripiprazole lauroxil should only be typically used under the guidance of a physician and that the medication may not be suitable for everyone.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
